Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Talazoparib demonstrates a moderate benefit over standard chemotherapy, with evidence from the EMBRACA trial showing a statistically significant improvement in progression-free survival (8.6 months vs. 5.6 months). However, there was no significant difference in overall survival, which limits the strength of the clinical effectiveness claim.
Cost effectiveness
The cost-effectiveness estimates for talazoparib are within the acceptable range for Healthcare resources, particularly when considering the severity of the condition and the potential for improved quality of life. The committee concluded that the ICER is acceptable, although there are uncertainties.
Quality of life
The evidence suggests that talazoparib is likely to improve quality of life compared to chemotherapy, as indicated by patient and clinical expert opinions. However, the data from the EMBRACA trial is subject to bias due to its open-label design, which introduces uncertainty.
Supporting Domains
Safety and Adverse Effects
Talazoparib has a very good safety profile, with mostly mild to moderate adverse events reported. The committee noted that the adverse effects are manageable and comparable to existing therapies, which supports its use.
Comparator Selection
The comparators used in the EMBRACA trial (physician’s choice of treatment including capecitabine, eribulin, and vinorelbine) are appropriate and reflect current clinical practice for the target population, ensuring relevance to the appraisal.
Patient Population and Subgroups
The trial population is considered to be representative of the intended patient population, including those with germline BRCA mutations. However, there are some concerns regarding heterogeneity in treatment pathways, which may affect generalizability.
Care Pathway Integration
Talazoparib can be integrated into existing treatment pathways with minor adjustments, as it offers an alternative to chemotherapy. The committee noted that it does not require significant changes to current practices.
Resource Use and Cost Implications
The resource implications of talazoparib are manageable, with the potential for cost savings due to reduced hospital visits compared to traditional chemotherapy. The committee acknowledged the economic model’s alignment with NICE’s methods.
Evidence Quality and Robustness
The evidence base is supported by a Phase 3 RCT (EMBRACA) with a robust design, although there are some limitations regarding the generalizability of the results due to the open-label nature of the trial.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the overall survival benefit and the impact of treatment sequencing, the committee found the context supportive of talazoparib’s use, particularly given the high unmet need in this patient population.
